Enter the expert review stage!

Recently, the National Medical Insurance Administration issued an announcement that the list of declared drugs announced at the beginning of this month has been reviewed and revised, and the results of the review of the 2021 National Medical Insurance Drug List adjustment form have been formally formed .
The next step will be to organize expert review and other related work
.

According to the previous progress description, the expert review stage will be conducted from August to September :

Comprehensive group review

According to the company's application status, establish a database of drugs for review
.

Professional group review

Organize experts to use evaluation indicators to demonstrate and evaluate drugs
.

Comprehensive group argument

The expert opinions of the professional group were demonstrated, and the drug list was finally determined in five aspects: direct new transfer, negotiation new transfer, direct transfer, possible transfer, and adjustment of the limited payment scope
.

Feedback result

Feedback the expert review results to the applying company
.

Since then, the 9 to 10 month entered the negotiation phase , 10 to November publication of the results
.

Attached original announcement:

Announcement of the National Medical Security Administration on the Inquiry of the Results of the Review of the Adjustment Form of the National Medical Insurance Drug Catalogue in 2021

From July 30 to August 5, 2021, the Bureau announced to the public the "List of Drugs Applicable for the 2021 National Medical Insurance Drug Catalog Adjustment Passed the Preliminary Formal Examination"
.

In the next step, our bureau will organize and carry out expert review and other related work in accordance with the relevant requirements of the "Interim Measures for the Administration of Drugs for Basic Medical Insurance" and the "Work Plan for the 2021 National Medical Insurance Drug List Adjustment"
.

National Medical Security Administration

August 27, 2021